International	O
Variation	O
in	O
Outcomes	B:C0086750
Among	O
People	O
with	O
Cardiovascular	O
Disease	I:C0007222
or	O
Cardiovascular	O
Risk	O
Factors	O
and	O
Impaired	O
Glucose	I:C0271650
Tolerance	I:C0271650
:	O
Insights	O
from	O
the	O
NAVIGATOR	O
Trial	I:C0159069
.	O

International	O
Variation	O
in	O
Outcomes	O
Among	O
People	O
with	O
Cardiovascular	B:C0007222
Disease	I:C0007222
or	O
Cardiovascular	O
Risk	O
Factors	O
and	O
Impaired	O
Glucose	I:C0271650
Tolerance	I:C0271650
:	O
Insights	O
from	O
the	O
NAVIGATOR	O
Trial	I:C0159069
.	O

International	O
Variation	O
in	O
Outcomes	O
Among	O
People	O
with	O
Cardiovascular	O
Disease	I:C0007222
or	O
Cardiovascular	O
Risk	O
Factors	O
and	O
Impaired	B:C0271650
Glucose	I:C0271650
Tolerance	I:C0271650
:	O
Insights	O
from	O
the	O
NAVIGATOR	O
Trial	I:C0159069
.	O

International	O
Variation	O
in	O
Outcomes	O
Among	O
People	O
with	O
Cardiovascular	O
Disease	I:C0007222
or	O
Cardiovascular	O
Risk	O
Factors	O
and	O
Impaired	O
Glucose	I:C0271650
Tolerance	I:C0271650
:	O
Insights	B:C0233820
from	O
the	O
NAVIGATOR	O
Trial	I:C0159069
.	O

International	O
Variation	O
in	O
Outcomes	O
Among	O
People	O
with	O
Cardiovascular	O
Disease	I:C0007222
or	O
Cardiovascular	O
Risk	O
Factors	O
and	O
Impaired	O
Glucose	I:C0271650
Tolerance	I:C0271650
:	O
Insights	O
from	O
the	O
NAVIGATOR	B:C0159069
Trial	I:C0159069
.	O

Regional	O
differences	O
in	O
risk	B:C0580321
of	I:C0580321
diabetes	I:C0580321
mellitus	I:C0580321
and	O
cardiovascular	O
outcomes	O
in	O
people	O
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
are	O
poorly	O
characterized	O
.	O

Regional	O
differences	O
in	O
risk	O
of	I:C0580321
diabetes	I:C0580321
mellitus	I:C0580321
and	O
cardiovascular	B:C3887460
outcomes	O
in	O
people	O
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
are	O
poorly	O
characterized	O
.	O

Regional	O
differences	O
in	O
risk	O
of	I:C0580321
diabetes	I:C0580321
mellitus	I:C0580321
and	O
cardiovascular	O
outcomes	B:C0086750
in	O
people	O
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
are	O
poorly	O
characterized	O
.	O

Regional	O
differences	O
in	O
risk	O
of	I:C0580321
diabetes	I:C0580321
mellitus	I:C0580321
and	O
cardiovascular	O
outcomes	O
in	O
people	B:C0027361
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
are	O
poorly	O
characterized	O
.	O

Regional	O
differences	O
in	O
risk	O
of	I:C0580321
diabetes	I:C0580321
mellitus	I:C0580321
and	O
cardiovascular	O
outcomes	O
in	O
people	O
with	O
impaired	B:C0271650
glucose	I:C0271650
tolerance	I:C0271650
are	O
poorly	O
characterized	O
.	O

Our	O
objective	O
was	O
to	O
evaluate	O
regional	B:C0205147
variation	O
in	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
outcomes	O
,	O
and	O
treatment	O
effects	I:C1518681
in	O
participants	O
from	O
the	O
Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
(	O
Nateglinide	O
and	O
Valsartan	O
in	O
Impaired	O
Glucose	I:C0271650
Tolerance	I:C0271650
Outcomes	O
Research	I:C0086750
)	O
trial	O
.	O

Our	O
objective	O
was	O
to	O
evaluate	O
regional	O
variation	O
in	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	B:C3887460
outcomes	O
,	O
and	O
treatment	O
effects	I:C1518681
in	O
participants	O
from	O
the	O
Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
(	O
Nateglinide	O
and	O
Valsartan	O
in	O
Impaired	O
Glucose	I:C0271650
Tolerance	I:C0271650
Outcomes	O
Research	I:C0086750
)	O
trial	O
.	O

Our	O
objective	O
was	O
to	O
evaluate	O
regional	O
variation	O
in	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
outcomes	B:C0086750
,	O
and	O
treatment	O
effects	I:C1518681
in	O
participants	O
from	O
the	O
Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
(	O
Nateglinide	O
and	O
Valsartan	O
in	O
Impaired	O
Glucose	I:C0271650
Tolerance	I:C0271650
Outcomes	O
Research	I:C0086750
)	O
trial	O
.	O

Our	O
objective	O
was	O
to	O
evaluate	O
regional	O
variation	O
in	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
outcomes	O
,	O
and	O
treatment	B:C1518681
effects	I:C1518681
in	O
participants	O
from	O
the	O
Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
(	O
Nateglinide	O
and	O
Valsartan	O
in	O
Impaired	O
Glucose	I:C0271650
Tolerance	I:C0271650
Outcomes	O
Research	I:C0086750
)	O
trial	O
.	O

Our	O
objective	O
was	O
to	O
evaluate	O
regional	O
variation	O
in	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
outcomes	O
,	O
and	O
treatment	O
effects	I:C1518681
in	O
participants	B:C0679646
from	O
the	O
Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
(	O
Nateglinide	O
and	O
Valsartan	O
in	O
Impaired	O
Glucose	I:C0271650
Tolerance	I:C0271650
Outcomes	O
Research	I:C0086750
)	O
trial	O
.	O

Our	O
objective	O
was	O
to	O
evaluate	O
regional	O
variation	O
in	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
outcomes	O
,	O
and	O
treatment	O
effects	I:C1518681
in	O
participants	O
from	O
the	O
Nateglinide	B:C0159069
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
(	O
Nateglinide	O
and	O
Valsartan	O
in	O
Impaired	O
Glucose	I:C0271650
Tolerance	I:C0271650
Outcomes	O
Research	I:C0086750
)	O
trial	O
.	O

Our	O
objective	O
was	O
to	O
evaluate	O
regional	O
variation	O
in	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
outcomes	O
,	O
and	O
treatment	O
effects	I:C1518681
in	O
participants	O
from	O
the	O
Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
(	O
Nateglinide	B:C0903898
and	O
Valsartan	O
in	O
Impaired	O
Glucose	I:C0271650
Tolerance	I:C0271650
Outcomes	O
Research	I:C0086750
)	O
trial	O
.	O

Our	O
objective	O
was	O
to	O
evaluate	O
regional	O
variation	O
in	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
outcomes	O
,	O
and	O
treatment	O
effects	I:C1518681
in	O
participants	O
from	O
the	O
Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
(	O
Nateglinide	O
and	O
Valsartan	B:C0216784
in	O
Impaired	O
Glucose	I:C0271650
Tolerance	I:C0271650
Outcomes	O
Research	I:C0086750
)	O
trial	O
.	O

Our	O
objective	O
was	O
to	O
evaluate	O
regional	O
variation	O
in	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
outcomes	O
,	O
and	O
treatment	O
effects	I:C1518681
in	O
participants	O
from	O
the	O
Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
(	O
Nateglinide	O
and	O
Valsartan	O
in	O
Impaired	B:C0271650
Glucose	I:C0271650
Tolerance	I:C0271650
Outcomes	O
Research	I:C0086750
)	O
trial	O
.	O

Our	O
objective	O
was	O
to	O
evaluate	O
regional	O
variation	O
in	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
outcomes	O
,	O
and	O
treatment	O
effects	I:C1518681
in	O
participants	O
from	O
the	O
Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
(	O
Nateglinide	O
and	O
Valsartan	O
in	O
Impaired	O
Glucose	I:C0271650
Tolerance	I:C0271650
Outcomes	B:C0086750
Research	I:C0086750
)	O
trial	O
.	O

Our	O
objective	O
was	O
to	O
evaluate	O
regional	O
variation	O
in	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
outcomes	O
,	O
and	O
treatment	O
effects	I:C1518681
in	O
participants	O
from	O
the	O
Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
(	O
Nateglinide	O
and	O
Valsartan	O
in	O
Impaired	O
Glucose	I:C0271650
Tolerance	I:C0271650
Outcomes	O
Research	I:C0086750
)	O
trial	B:C0159069
.	O

Nateglinide	B:C0159069
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
randomized	O
people	O
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
and	O
cardiovascular	O
risk	O
factors	O
or	O
with	O
established	O
cardiovascular	O
disease	I:C0007222
to	O
valsartan	O
(	O
or	O
placebo	O
)	O
and	O
to	O
nateglinide	O
(	O
or	O
placebo	O
)	O
with	O
a	O
median	O
5	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
randomized	B:C0034656
people	O
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
and	O
cardiovascular	O
risk	O
factors	O
or	O
with	O
established	O
cardiovascular	O
disease	I:C0007222
to	O
valsartan	O
(	O
or	O
placebo	O
)	O
and	O
to	O
nateglinide	O
(	O
or	O
placebo	O
)	O
with	O
a	O
median	O
5	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
randomized	O
people	B:C0027361
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
and	O
cardiovascular	O
risk	O
factors	O
or	O
with	O
established	O
cardiovascular	O
disease	I:C0007222
to	O
valsartan	O
(	O
or	O
placebo	O
)	O
and	O
to	O
nateglinide	O
(	O
or	O
placebo	O
)	O
with	O
a	O
median	O
5	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
randomized	O
people	O
with	O
impaired	B:C0271650
glucose	I:C0271650
tolerance	I:C0271650
and	O
cardiovascular	O
risk	O
factors	O
or	O
with	O
established	O
cardiovascular	O
disease	I:C0007222
to	O
valsartan	O
(	O
or	O
placebo	O
)	O
and	O
to	O
nateglinide	O
(	O
or	O
placebo	O
)	O
with	O
a	O
median	O
5	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
randomized	O
people	O
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
and	O
cardiovascular	O
risk	O
factors	O
or	O
with	O
established	O
cardiovascular	B:C0007222
disease	I:C0007222
to	O
valsartan	O
(	O
or	O
placebo	O
)	O
and	O
to	O
nateglinide	O
(	O
or	O
placebo	O
)	O
with	O
a	O
median	O
5	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
randomized	O
people	O
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
and	O
cardiovascular	O
risk	O
factors	O
or	O
with	O
established	O
cardiovascular	O
disease	I:C0007222
to	O
valsartan	B:C0216784
(	O
or	O
placebo	O
)	O
and	O
to	O
nateglinide	O
(	O
or	O
placebo	O
)	O
with	O
a	O
median	O
5	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
randomized	O
people	O
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
and	O
cardiovascular	O
risk	O
factors	O
or	O
with	O
established	O
cardiovascular	O
disease	I:C0007222
to	O
valsartan	O
(	O
or	O
placebo	B:C1696465
)	O
and	O
to	O
nateglinide	O
(	O
or	O
placebo	O
)	O
with	O
a	O
median	O
5	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
randomized	O
people	O
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
and	O
cardiovascular	O
risk	O
factors	O
or	O
with	O
established	O
cardiovascular	O
disease	I:C0007222
to	O
valsartan	O
(	O
or	O
placebo	O
)	O
and	O
to	O
nateglinide	B:C0903898
(	O
or	O
placebo	O
)	O
with	O
a	O
median	O
5	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
randomized	O
people	O
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
and	O
cardiovascular	O
risk	O
factors	O
or	O
with	O
established	O
cardiovascular	O
disease	I:C0007222
to	O
valsartan	O
(	O
or	O
placebo	O
)	O
and	O
to	O
nateglinide	O
(	O
or	O
placebo	B:C1696465
)	O
with	O
a	O
median	O
5	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
randomized	O
people	O
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
and	O
cardiovascular	O
risk	O
factors	O
or	O
with	O
established	O
cardiovascular	O
disease	I:C0007222
to	O
valsartan	O
(	O
or	O
placebo	O
)	O
and	O
to	O
nateglinide	O
(	O
or	O
placebo	O
)	O
with	O
a	O
median	B:C2939193
5	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
randomized	O
people	O
with	O
impaired	O
glucose	I:C0271650
tolerance	I:C0271650
and	O
cardiovascular	O
risk	O
factors	O
or	O
with	O
established	O
cardiovascular	O
disease	I:C0007222
to	O
valsartan	O
(	O
or	O
placebo	O
)	O
and	O
to	O
nateglinide	O
(	O
or	O
placebo	O
)	O
with	O
a	O
median	O
5	O
-	O
year	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
.	O

Data	O
from	O
the	O
9306	O
participants	B:C0679646
were	O
categorized	O
by	O
5	O
regions	O
:	O
Asia	O
(	O
n=552	O
)	O
;	O
Europe	O
(	O
n=4909	O
)	O
;	O
Latin	O
America	I:C0023122
(	O
n=1406	O
)	O
;	O
North	O
America	I:C0028405
(	O
n=2146	O
)	O
;	O
and	O
Australia	O
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
(	O
n=293	O
)	O
.	O

Data	O
from	O
the	O
9306	O
participants	O
were	O
categorized	O
by	O
5	O
regions	B:C0017446
:	O
Asia	O
(	O
n=552	O
)	O
;	O
Europe	O
(	O
n=4909	O
)	O
;	O
Latin	O
America	I:C0023122
(	O
n=1406	O
)	O
;	O
North	O
America	I:C0028405
(	O
n=2146	O
)	O
;	O
and	O
Australia	O
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
(	O
n=293	O
)	O
.	O

Data	O
from	O
the	O
9306	O
participants	O
were	O
categorized	O
by	O
5	O
regions	O
:	O
Asia	B:C0003980
(	O
n=552	O
)	O
;	O
Europe	O
(	O
n=4909	O
)	O
;	O
Latin	O
America	I:C0023122
(	O
n=1406	O
)	O
;	O
North	O
America	I:C0028405
(	O
n=2146	O
)	O
;	O
and	O
Australia	O
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
(	O
n=293	O
)	O
.	O

Data	O
from	O
the	O
9306	O
participants	O
were	O
categorized	O
by	O
5	O
regions	O
:	O
Asia	O
(	O
n=552	O
)	O
;	O
Europe	B:C0015176
(	O
n=4909	O
)	O
;	O
Latin	O
America	I:C0023122
(	O
n=1406	O
)	O
;	O
North	O
America	I:C0028405
(	O
n=2146	O
)	O
;	O
and	O
Australia	O
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
(	O
n=293	O
)	O
.	O

Data	O
from	O
the	O
9306	O
participants	O
were	O
categorized	O
by	O
5	O
regions	O
:	O
Asia	O
(	O
n=552	O
)	O
;	O
Europe	O
(	O
n=4909	O
)	O
;	O
Latin	B:C0023122
America	I:C0023122
(	O
n=1406	O
)	O
;	O
North	O
America	I:C0028405
(	O
n=2146	O
)	O
;	O
and	O
Australia	O
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
(	O
n=293	O
)	O
.	O

Data	O
from	O
the	O
9306	O
participants	O
were	O
categorized	O
by	O
5	O
regions	O
:	O
Asia	O
(	O
n=552	O
)	O
;	O
Europe	O
(	O
n=4909	O
)	O
;	O
Latin	O
America	I:C0023122
(	O
n=1406	O
)	O
;	O
North	B:C0028405
America	I:C0028405
(	O
n=2146	O
)	O
;	O
and	O
Australia	O
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
(	O
n=293	O
)	O
.	O

Data	O
from	O
the	O
9306	O
participants	O
were	O
categorized	O
by	O
5	O
regions	O
:	O
Asia	O
(	O
n=552	O
)	O
;	O
Europe	O
(	O
n=4909	O
)	O
;	O
Latin	O
America	I:C0023122
(	O
n=1406	O
)	O
;	O
North	O
America	I:C0028405
(	O
n=2146	O
)	O
;	O
and	O
Australia	B:C0004340
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
(	O
n=293	O
)	O
.	O

Data	O
from	O
the	O
9306	O
participants	O
were	O
categorized	O
by	O
5	O
regions	O
:	O
Asia	O
(	O
n=552	O
)	O
;	O
Europe	O
(	O
n=4909	O
)	O
;	O
Latin	O
America	I:C0023122
(	O
n=1406	O
)	O
;	O
North	O
America	I:C0028405
(	O
n=2146	O
)	O
;	O
and	O
Australia	O
,	O
New	B:C0027978
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
(	O
n=293	O
)	O
.	O

Data	O
from	O
the	O
9306	O
participants	O
were	O
categorized	O
by	O
5	O
regions	O
:	O
Asia	O
(	O
n=552	O
)	O
;	O
Europe	O
(	O
n=4909	O
)	O
;	O
Latin	O
America	I:C0023122
(	O
n=1406	O
)	O
;	O
North	O
America	I:C0028405
(	O
n=2146	O
)	O
;	O
and	O
Australia	O
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	B:C0037712
Africa	I:C0037712
(	O
n=293	O
)	O
.	O

Analyzed	O
outcomes	B:C0086750
included	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
;	O
cardiovascular	O
death	O
;	O
a	O
composite	O
cardiovascular	O
outcome	O
of	O
cardiovascular	O
death	O
,	O
nonfatal	O
myocardial	O
infarction	I:C0027051
,	O
or	O
nonfatal	O
stroke	O
;	O
and	O
treatment	O
effects	I:C1518681
of	O
valsartan	O
and	O
nateglinide	O
.	O

Analyzed	O
outcomes	O
included	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
;	O
cardiovascular	B:C3887460
death	O
;	O
a	O
composite	O
cardiovascular	O
outcome	O
of	O
cardiovascular	O
death	O
,	O
nonfatal	O
myocardial	O
infarction	I:C0027051
,	O
or	O
nonfatal	O
stroke	O
;	O
and	O
treatment	O
effects	I:C1518681
of	O
valsartan	O
and	O
nateglinide	O
.	O

Analyzed	O
outcomes	O
included	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
;	O
cardiovascular	O
death	B:C1306577
;	O
a	O
composite	O
cardiovascular	O
outcome	O
of	O
cardiovascular	O
death	O
,	O
nonfatal	O
myocardial	O
infarction	I:C0027051
,	O
or	O
nonfatal	O
stroke	O
;	O
and	O
treatment	O
effects	I:C1518681
of	O
valsartan	O
and	O
nateglinide	O
.	O

Analyzed	O
outcomes	O
included	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
;	O
cardiovascular	O
death	O
;	O
a	O
composite	O
cardiovascular	B:C3887460
outcome	O
of	O
cardiovascular	O
death	O
,	O
nonfatal	O
myocardial	O
infarction	I:C0027051
,	O
or	O
nonfatal	O
stroke	O
;	O
and	O
treatment	O
effects	I:C1518681
of	O
valsartan	O
and	O
nateglinide	O
.	O

Analyzed	O
outcomes	O
included	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
;	O
cardiovascular	O
death	O
;	O
a	O
composite	O
cardiovascular	O
outcome	B:C0086750
of	O
cardiovascular	O
death	O
,	O
nonfatal	O
myocardial	O
infarction	I:C0027051
,	O
or	O
nonfatal	O
stroke	O
;	O
and	O
treatment	O
effects	I:C1518681
of	O
valsartan	O
and	O
nateglinide	O
.	O

Analyzed	O
outcomes	O
included	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
;	O
cardiovascular	O
death	O
;	O
a	O
composite	O
cardiovascular	O
outcome	O
of	O
cardiovascular	B:C3887460
death	O
,	O
nonfatal	O
myocardial	O
infarction	I:C0027051
,	O
or	O
nonfatal	O
stroke	O
;	O
and	O
treatment	O
effects	I:C1518681
of	O
valsartan	O
and	O
nateglinide	O
.	O

Analyzed	O
outcomes	O
included	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
;	O
cardiovascular	O
death	O
;	O
a	O
composite	O
cardiovascular	O
outcome	O
of	O
cardiovascular	O
death	B:C1306577
,	O
nonfatal	O
myocardial	O
infarction	I:C0027051
,	O
or	O
nonfatal	O
stroke	O
;	O
and	O
treatment	O
effects	I:C1518681
of	O
valsartan	O
and	O
nateglinide	O
.	O

Analyzed	O
outcomes	O
included	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
;	O
cardiovascular	O
death	O
;	O
a	O
composite	O
cardiovascular	O
outcome	O
of	O
cardiovascular	O
death	O
,	O
nonfatal	O
myocardial	B:C0027051
infarction	I:C0027051
,	O
or	O
nonfatal	O
stroke	O
;	O
and	O
treatment	O
effects	I:C1518681
of	O
valsartan	O
and	O
nateglinide	O
.	O

Analyzed	O
outcomes	O
included	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
;	O
cardiovascular	O
death	O
;	O
a	O
composite	O
cardiovascular	O
outcome	O
of	O
cardiovascular	O
death	O
,	O
nonfatal	O
myocardial	O
infarction	I:C0027051
,	O
or	O
nonfatal	O
stroke	B:C0038454
;	O
and	O
treatment	O
effects	I:C1518681
of	O
valsartan	O
and	O
nateglinide	O
.	O

Analyzed	O
outcomes	O
included	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
;	O
cardiovascular	O
death	O
;	O
a	O
composite	O
cardiovascular	O
outcome	O
of	O
cardiovascular	O
death	O
,	O
nonfatal	O
myocardial	O
infarction	I:C0027051
,	O
or	O
nonfatal	O
stroke	O
;	O
and	O
treatment	B:C1518681
effects	I:C1518681
of	O
valsartan	O
and	O
nateglinide	O
.	O

Analyzed	O
outcomes	O
included	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
;	O
cardiovascular	O
death	O
;	O
a	O
composite	O
cardiovascular	O
outcome	O
of	O
cardiovascular	O
death	O
,	O
nonfatal	O
myocardial	O
infarction	I:C0027051
,	O
or	O
nonfatal	O
stroke	O
;	O
and	O
treatment	O
effects	I:C1518681
of	O
valsartan	B:C0216784
and	O
nateglinide	O
.	O

Analyzed	O
outcomes	O
included	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
;	O
cardiovascular	O
death	O
;	O
a	O
composite	O
cardiovascular	O
outcome	O
of	O
cardiovascular	O
death	O
,	O
nonfatal	O
myocardial	O
infarction	I:C0027051
,	O
or	O
nonfatal	O
stroke	O
;	O
and	O
treatment	O
effects	I:C1518681
of	O
valsartan	O
and	O
nateglinide	B:C0903898
.	O

Respective	O
unadjusted	O
5	O
-	O
year	O
risks	O
for	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	B:C3887460
death	O
,	O
and	O
the	O
composite	O
cardiovascular	O
outcome	O
were	O
33	O
%	O
,	O
0.4	O
%	O
,	O
and	O
4	O
%	O
for	O
Asia	O
;	O
34	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
Europe	O
;	O
37	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Latin	O
America	I:C0023122
;	O
38	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
North	O
America	I:C0028405
;	O
and	O
32	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Australia	O
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
.	O

Respective	O
unadjusted	O
5	O
-	O
year	O
risks	O
for	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
death	B:C1306577
,	O
and	O
the	O
composite	O
cardiovascular	O
outcome	O
were	O
33	O
%	O
,	O
0.4	O
%	O
,	O
and	O
4	O
%	O
for	O
Asia	O
;	O
34	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
Europe	O
;	O
37	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Latin	O
America	I:C0023122
;	O
38	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
North	O
America	I:C0028405
;	O
and	O
32	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Australia	O
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
.	O

Respective	O
unadjusted	O
5	O
-	O
year	O
risks	O
for	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
death	O
,	O
and	O
the	O
composite	O
cardiovascular	B:C3887460
outcome	O
were	O
33	O
%	O
,	O
0.4	O
%	O
,	O
and	O
4	O
%	O
for	O
Asia	O
;	O
34	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
Europe	O
;	O
37	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Latin	O
America	I:C0023122
;	O
38	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
North	O
America	I:C0028405
;	O
and	O
32	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Australia	O
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
.	O

Respective	O
unadjusted	O
5	O
-	O
year	O
risks	O
for	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
death	O
,	O
and	O
the	O
composite	O
cardiovascular	O
outcome	B:C0086750
were	O
33	O
%	O
,	O
0.4	O
%	O
,	O
and	O
4	O
%	O
for	O
Asia	O
;	O
34	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
Europe	O
;	O
37	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Latin	O
America	I:C0023122
;	O
38	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
North	O
America	I:C0028405
;	O
and	O
32	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Australia	O
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
.	O

Respective	O
unadjusted	O
5	O
-	O
year	O
risks	O
for	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
death	O
,	O
and	O
the	O
composite	O
cardiovascular	O
outcome	O
were	O
33	O
%	O
,	O
0.4	O
%	O
,	O
and	O
4	O
%	O
for	O
Asia	B:C0003980
;	O
34	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
Europe	O
;	O
37	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Latin	O
America	I:C0023122
;	O
38	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
North	O
America	I:C0028405
;	O
and	O
32	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Australia	O
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
.	O

Respective	O
unadjusted	O
5	O
-	O
year	O
risks	O
for	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
death	O
,	O
and	O
the	O
composite	O
cardiovascular	O
outcome	O
were	O
33	O
%	O
,	O
0.4	O
%	O
,	O
and	O
4	O
%	O
for	O
Asia	O
;	O
34	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
Europe	B:C0015176
;	O
37	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Latin	O
America	I:C0023122
;	O
38	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
North	O
America	I:C0028405
;	O
and	O
32	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Australia	O
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
.	O

Respective	O
unadjusted	O
5	O
-	O
year	O
risks	O
for	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
death	O
,	O
and	O
the	O
composite	O
cardiovascular	O
outcome	O
were	O
33	O
%	O
,	O
0.4	O
%	O
,	O
and	O
4	O
%	O
for	O
Asia	O
;	O
34	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
Europe	O
;	O
37	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Latin	B:C0023122
America	I:C0023122
;	O
38	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
North	O
America	I:C0028405
;	O
and	O
32	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Australia	O
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
.	O

Respective	O
unadjusted	O
5	O
-	O
year	O
risks	O
for	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
death	O
,	O
and	O
the	O
composite	O
cardiovascular	O
outcome	O
were	O
33	O
%	O
,	O
0.4	O
%	O
,	O
and	O
4	O
%	O
for	O
Asia	O
;	O
34	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
Europe	O
;	O
37	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Latin	O
America	I:C0023122
;	O
38	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
North	B:C0028405
America	I:C0028405
;	O
and	O
32	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Australia	O
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
.	O

Respective	O
unadjusted	O
5	O
-	O
year	O
risks	O
for	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
death	O
,	O
and	O
the	O
composite	O
cardiovascular	O
outcome	O
were	O
33	O
%	O
,	O
0.4	O
%	O
,	O
and	O
4	O
%	O
for	O
Asia	O
;	O
34	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
Europe	O
;	O
37	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Latin	O
America	I:C0023122
;	O
38	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
North	O
America	I:C0028405
;	O
and	O
32	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Australia	B:C0004340
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
.	O

Respective	O
unadjusted	O
5	O
-	O
year	O
risks	O
for	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
death	O
,	O
and	O
the	O
composite	O
cardiovascular	O
outcome	O
were	O
33	O
%	O
,	O
0.4	O
%	O
,	O
and	O
4	O
%	O
for	O
Asia	O
;	O
34	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
Europe	O
;	O
37	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Latin	O
America	I:C0023122
;	O
38	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
North	O
America	I:C0028405
;	O
and	O
32	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Australia	O
,	O
New	B:C0027978
Zealand	I:C0027978
,	O
and	O
South	O
Africa	I:C0037712
.	O

Respective	O
unadjusted	O
5	O
-	O
year	O
risks	O
for	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
death	O
,	O
and	O
the	O
composite	O
cardiovascular	O
outcome	O
were	O
33	O
%	O
,	O
0.4	O
%	O
,	O
and	O
4	O
%	O
for	O
Asia	O
;	O
34	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
Europe	O
;	O
37	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Latin	O
America	I:C0023122
;	O
38	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
for	O
North	O
America	I:C0028405
;	O
and	O
32	O
%	O
,	O
4	O
%	O
,	O
and	O
8	O
%	O
for	O
Australia	O
,	O
New	O
Zealand	I:C0027978
,	O
and	O
South	B:C0037712
Africa	I:C0037712
.	O

After	O
adjustment	O
,	O
compared	O
with	O
North	B:C0028405
America	I:C0028405
,	O
European	O
participants	O
had	O
a	O
lower	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
(	O
hazard	O
ratio	O
0.86	O
,	O
95	O
%	O
CI	O
0.78-0.94	O
;	O
P=0.001	O
)	O
,	O
whereas	O
Latin	O
American	I:C1553378
participants	O
had	O
a	O
higher	O
risk	O
of	O
cardiovascular	O
death	O
(	O
hazard	O
ratio	O
2.68	O
,	O
95	O
%	O
CI	O
1.82-3.96	O
;	O
P	O
<	O
0.0001	O
)	O
and	O
the	O
composite	O
cardiovascular	O
outcome	O
(	O
hazard	O
ratio	O
1.48	O
,	O
95	O
%	O
CI	O
1.15	O
-	O
1.92	O
;	O
P=0.003	O
)	O
.	O

After	O
adjustment	O
,	O
compared	O
with	O
North	O
America	I:C0028405
,	O
European	B:C0239307
participants	O
had	O
a	O
lower	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
(	O
hazard	O
ratio	O
0.86	O
,	O
95	O
%	O
CI	O
0.78-0.94	O
;	O
P=0.001	O
)	O
,	O
whereas	O
Latin	O
American	I:C1553378
participants	O
had	O
a	O
higher	O
risk	O
of	O
cardiovascular	O
death	O
(	O
hazard	O
ratio	O
2.68	O
,	O
95	O
%	O
CI	O
1.82-3.96	O
;	O
P	O
<	O
0.0001	O
)	O
and	O
the	O
composite	O
cardiovascular	O
outcome	O
(	O
hazard	O
ratio	O
1.48	O
,	O
95	O
%	O
CI	O
1.15	O
-	O
1.92	O
;	O
P=0.003	O
)	O
.	O

After	O
adjustment	O
,	O
compared	O
with	O
North	O
America	I:C0028405
,	O
European	O
participants	B:C0679646
had	O
a	O
lower	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
(	O
hazard	O
ratio	O
0.86	O
,	O
95	O
%	O
CI	O
0.78-0.94	O
;	O
P=0.001	O
)	O
,	O
whereas	O
Latin	O
American	I:C1553378
participants	O
had	O
a	O
higher	O
risk	O
of	O
cardiovascular	O
death	O
(	O
hazard	O
ratio	O
2.68	O
,	O
95	O
%	O
CI	O
1.82-3.96	O
;	O
P	O
<	O
0.0001	O
)	O
and	O
the	O
composite	O
cardiovascular	O
outcome	O
(	O
hazard	O
ratio	O
1.48	O
,	O
95	O
%	O
CI	O
1.15	O
-	O
1.92	O
;	O
P=0.003	O
)	O
.	O

After	O
adjustment	O
,	O
compared	O
with	O
North	O
America	I:C0028405
,	O
European	O
participants	O
had	O
a	O
lower	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
(	O
hazard	O
ratio	O
0.86	O
,	O
95	O
%	O
CI	O
0.78-0.94	O
;	O
P=0.001	O
)	O
,	O
whereas	O
Latin	B:C1553378
American	I:C1553378
participants	O
had	O
a	O
higher	O
risk	O
of	O
cardiovascular	O
death	O
(	O
hazard	O
ratio	O
2.68	O
,	O
95	O
%	O
CI	O
1.82-3.96	O
;	O
P	O
<	O
0.0001	O
)	O
and	O
the	O
composite	O
cardiovascular	O
outcome	O
(	O
hazard	O
ratio	O
1.48	O
,	O
95	O
%	O
CI	O
1.15	O
-	O
1.92	O
;	O
P=0.003	O
)	O
.	O

After	O
adjustment	O
,	O
compared	O
with	O
North	O
America	I:C0028405
,	O
European	O
participants	O
had	O
a	O
lower	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
(	O
hazard	O
ratio	O
0.86	O
,	O
95	O
%	O
CI	O
0.78-0.94	O
;	O
P=0.001	O
)	O
,	O
whereas	O
Latin	O
American	I:C1553378
participants	B:C0679646
had	O
a	O
higher	O
risk	O
of	O
cardiovascular	O
death	O
(	O
hazard	O
ratio	O
2.68	O
,	O
95	O
%	O
CI	O
1.82-3.96	O
;	O
P	O
<	O
0.0001	O
)	O
and	O
the	O
composite	O
cardiovascular	O
outcome	O
(	O
hazard	O
ratio	O
1.48	O
,	O
95	O
%	O
CI	O
1.15	O
-	O
1.92	O
;	O
P=0.003	O
)	O
.	O

After	O
adjustment	O
,	O
compared	O
with	O
North	O
America	I:C0028405
,	O
European	O
participants	O
had	O
a	O
lower	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
(	O
hazard	O
ratio	O
0.86	O
,	O
95	O
%	O
CI	O
0.78-0.94	O
;	O
P=0.001	O
)	O
,	O
whereas	O
Latin	O
American	I:C1553378
participants	O
had	O
a	O
higher	O
risk	O
of	O
cardiovascular	B:C3887460
death	O
(	O
hazard	O
ratio	O
2.68	O
,	O
95	O
%	O
CI	O
1.82-3.96	O
;	O
P	O
<	O
0.0001	O
)	O
and	O
the	O
composite	O
cardiovascular	O
outcome	O
(	O
hazard	O
ratio	O
1.48	O
,	O
95	O
%	O
CI	O
1.15	O
-	O
1.92	O
;	O
P=0.003	O
)	O
.	O

After	O
adjustment	O
,	O
compared	O
with	O
North	O
America	I:C0028405
,	O
European	O
participants	O
had	O
a	O
lower	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
(	O
hazard	O
ratio	O
0.86	O
,	O
95	O
%	O
CI	O
0.78-0.94	O
;	O
P=0.001	O
)	O
,	O
whereas	O
Latin	O
American	I:C1553378
participants	O
had	O
a	O
higher	O
risk	O
of	O
cardiovascular	O
death	B:C1306577
(	O
hazard	O
ratio	O
2.68	O
,	O
95	O
%	O
CI	O
1.82-3.96	O
;	O
P	O
<	O
0.0001	O
)	O
and	O
the	O
composite	O
cardiovascular	O
outcome	O
(	O
hazard	O
ratio	O
1.48	O
,	O
95	O
%	O
CI	O
1.15	O
-	O
1.92	O
;	O
P=0.003	O
)	O
.	O

After	O
adjustment	O
,	O
compared	O
with	O
North	O
America	I:C0028405
,	O
European	O
participants	O
had	O
a	O
lower	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
(	O
hazard	O
ratio	O
0.86	O
,	O
95	O
%	O
CI	O
0.78-0.94	O
;	O
P=0.001	O
)	O
,	O
whereas	O
Latin	O
American	I:C1553378
participants	O
had	O
a	O
higher	O
risk	O
of	O
cardiovascular	O
death	O
(	O
hazard	O
ratio	O
2.68	O
,	O
95	O
%	O
CI	O
1.82-3.96	O
;	O
P	O
<	O
0.0001	O
)	O
and	O
the	O
composite	O
cardiovascular	B:C3887460
outcome	O
(	O
hazard	O
ratio	O
1.48	O
,	O
95	O
%	O
CI	O
1.15	O
-	O
1.92	O
;	O
P=0.003	O
)	O
.	O

After	O
adjustment	O
,	O
compared	O
with	O
North	O
America	I:C0028405
,	O
European	O
participants	O
had	O
a	O
lower	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
(	O
hazard	O
ratio	O
0.86	O
,	O
95	O
%	O
CI	O
0.78-0.94	O
;	O
P=0.001	O
)	O
,	O
whereas	O
Latin	O
American	I:C1553378
participants	O
had	O
a	O
higher	O
risk	O
of	O
cardiovascular	O
death	O
(	O
hazard	O
ratio	O
2.68	O
,	O
95	O
%	O
CI	O
1.82-3.96	O
;	O
P	O
<	O
0.0001	O
)	O
and	O
the	O
composite	O
cardiovascular	O
outcome	B:C0086750
(	O
hazard	O
ratio	O
1.48	O
,	O
95	O
%	O
CI	O
1.15	O
-	O
1.92	O
;	O
P=0.003	O
)	O
.	O

No	O
differential	O
interactions	O
between	B:C0205103
treatment	O
and	O
geographic	O
location	I:C0017446
were	O
identified	O
.	O

No	O
differential	O
interactions	O
between	O
treatment	O
and	O
geographic	B:C0017446
location	I:C0017446
were	O
identified	O
.	O

Major	O
regional	O
differences	O
regarding	O
the	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
and	O
cardiovascular	B:C3887460
outcomes	O
in	O
Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
participants	O
were	O
identified	O
.	O

Major	O
regional	O
differences	O
regarding	O
the	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
and	O
cardiovascular	O
outcomes	B:C0086750
in	O
Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
participants	O
were	O
identified	O
.	O

Major	O
regional	O
differences	O
regarding	O
the	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
and	O
cardiovascular	O
outcomes	O
in	O
Nateglinide	B:C0159069
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
participants	O
were	O
identified	O
.	O

Major	O
regional	O
differences	O
regarding	O
the	O
risk	O
of	O
new	O
-	O
onset	O
diabetes	O
mellitus	O
and	O
cardiovascular	O
outcomes	O
in	O
Nateglinide	O
and	I:C0159069
Valsartan	I:C0159069
in	I:C0159069
Impaired	I:C0159069
Glucose	I:C0159069
Tolerance	I:C0159069
Outcomes	I:C0159069
Research	I:C0159069
participants	B:C0679646
were	O
identified	O
.	O

These	O
differences	O
should	O
be	O
taken	O
into	O
account	O
when	O
planning	O
global	O
trials	B:C0008976
.	O

